Comparison between overall survival in a high-risk AML cohort and BCR-ABL⁺AML. Overall survival in a high-risk AML cohort after allogeneic HSCT at Charité University Medical Center between 1997 and 2015. In comparison, the BCR-ABL⁺ AML cohorts from the European Society for Blood and Marrow Transplantation and French Society of Bone Marrow Transplantation (SFGM-TC) are included (data from Chantepie et al¹¹  and Lazarevic et al¹² ).